NDA 022369 · Abbvie
Latisse
Bimatoprost · Topical · Prostaglandin Analog
Priority reviewLast checked: Nov 20, 2026Latest source record: Aug 26, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2008
Dec 24, 2008
Approved uses
2
Original approval plus efficacy supplements
Registered trials
147
39 Phase 3, 7 recruiting
FAERS reports
11,267
1,810 serious, 132 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 1, 2024.
LATISSE ® (bimatoprost ophthalmic solution) 0.03% is indicated to treat hypotrichosis of the eyelashes by increasing their growth including length, thickness and darkness. LATISSE ® is a prostaglandin analog, indicated to treat hypotrichosis of the eyelashes by increasing their growth including length, thickness and darkness. ( 1 )
Mechanism: Bimatoprost is a structural prostaglandin analog. Although the precise mechanism of action is unknown, the growth of eyelashes is believed to occur by increasing the percent of hairs in, and the duration of the anagen or growth phase.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 4, 2014 Supplement 10 · Efficacy · priority review Pediatric DD Summary ReviewPediatric CDTL ReviewPediatric Medical Review
- Dec 24, 2008 Original approval · Type 5 - New Formulation or New Manufacturer · priority review LabelReviewSummary Review
1 products under this application
- LATISSE · BIMATOPROST 0.03% · SOLUTION/DROPS, TOPICAL · Prescription · TE AT
Clinical trials
Interventional ClinicalTrials.gov studies with "Bimatoprost" as an intervention, any sponsor and status, largest first.
AllerganAbbVie (ABBV)
NCT01833741 · 1,137 participants · Start Dec 2009 · Primary completion Mar 2011
Drug: Bimatoprost 0.01% · For: Glaucoma, Primary Open Angle; Ocular Hypertension
Sites: Barrie, Canada
- Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular HypertensionPivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT01298700 · 806 participants · Start May 31, 2011 · Primary completion Dec 6, 2016
Drug: bimatoprost 0.01% ophthalmic solution; bimatoprost 0.03% ophthalmic solution · For: Glaucoma; Ocular Hypertension
Sites: Leuven, Belgium; Liège, Belgium; Brno, Czechia · 50 sites in all
AllerganAbbVie (ABBV)
NCT01594970 · 800 participants · Start Mar 2012 · Primary completion Jan 2013
Drug: Bimatoprost 0.01% · For: Glaucoma, Open-Angle; Ocular Hypertension
Sites: Seoul, South Korea
AllerganAbbVie (ABBV)
NCT02571712 · 750 participants · Start Nov 10, 2015 · Primary completion Jun 21, 2018
Drug: bimatoprost 0.03% plus timolol 0.5% · For: Glaucoma, Open-Angle; Ocular Hypertension
Sites: Beijing, China; Guangzhou, China; Wuhan, China · 15 sites in all
- Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous PatientsPivotal-lookingCompleted
Laboratoires TheaIndustry
NCT05397600 · 684 participants · Start Jun 22, 2022 · Primary completion Mar 7, 2024
Drug: Bimatoprost Ophthalmic · For: Glaucoma; Ocular Hypertension
Sites: Chandler, Arizona; Glendale, Arizona; Phoenix, Arizona · 64 sites in all
- A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular HypertensionPivotal-lookingRecruiting
YS Life Science Co., Ltd.Industry
NCT07661329 · 600 participants (planned) · Start Jun 2, 2026 · Primary completion Nov 1, 2027
Drug: Bimatoprost ophthalmic solution 0.01% YSBP; bimatoprost ophthalmic solution 0.01% (Lumigan®) · For: Primary Open Angle Glaucoma (POAG); Ocular Hypertension (OH)
Sites: Beverly Hills, California; Inglewood, California; Newport Beach, California · 22 sites in all
- Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular HypertensionPivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT01099774 · 597 participants · Start May 1, 2010 · Primary completion Apr 29, 2011
Drug: Bimatoprost 0.03% Formulation B Ophthalmic Solution; Bimatoprost 0.03% Ophthalmic Solution · For: Glaucoma; Ocular Hypertension
Sites: Newport Beach, California
- Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular HypertensionPivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT02247804 · 594 participants · Start Dec 15, 2014 · Primary completion Feb 19, 2018
Drug: Bimatoprost SR; Active Comparator: Timolol 0.5% and 1 more · For: Glaucoma, Open-Angle; Ocular Hypertension
Sites: Phoenix, Arizona; Glendale, California; Irvine, California · 106 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective2,432
- ocular hyperaemia1,482
- madarosis1,369
- eye irritation1,024
- eye pruritus965
- erythema of eyelid901
- eyelids pruritus482
- eye swelling481
- wrong technique in product usage process454
- wrong technique in drug usage process384
- eyelid oedema375
- inappropriate schedule of drug administration373
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 10 |
| 2005 | 4 |
| 2006 | 8 |
| 2007 | 12 |
| 2008 | 21 |
| 2009 | 397 |
| 2010 | 1,527 |
| 2011 | 886 |
| 2012 | 513 |
| 2013 | 66 |
| 2014 | 95 |
| 2015 | 1,039 |
| 2016 | 1,023 |
| 2017 | 1,070 |
| 2018 | 834 |
| 2019 | 698 |
| 2020 | 635 |
| 2021 | 505 |
| 2022 | 400 |
| 2023 | 596 |
| 2024 | 394 |
| 2025 | 302 |
| 2026 | 232 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis.
Li T, Lindsley K, Rouse B, et al. · Ophthalmology 2016 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- MERCURY-3: a randomized comparison of netarsudil/latanoprost and bimatoprost/timolol in open-angle glaucoma and ocular hypertension.
Stalmans I, Lim KS, Oddone F, et al. · Graefes Arch Clin Exp Ophthalmol 2024 · Randomized Controlled Trial, Multicenter Study
- Prostaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma: a systematic review and meta-analysis.
Quaranta L, Biagioli E, Riva I, et al. · J Ocul Pharmacol Ther 2013 · Comparative Study, Meta-Analysis
- Bimatoprost vs. timolol.
Camras CB · Ophthalmology 2002 · Clinical Trial, Comment
- The efficacy of the fixed combination of latanoprost and timolol versus other fixed combinations for primary open-angle glaucoma and ocular hypertension: A systematic review and meta-analysis.
Xing Y, Zhu L, Zhang K, et al. · PLoS One 2020 · Meta-Analysis, Systematic Review
- Enhancing hair regrowth in Alopecia areata: the power duo of CO2 fractional laser and Bimatoprost.
Nouh AH, Behairy AAE, El-Koumy FB, et al. · Arch Dermatol Res 2025 · Randomized Controlled Trial
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.